Philogen S.p.A.

Equities

PHIL

IT0005373789

Biotechnology & Medical Research

Market Closed - Borsa Italiana Other stock markets 11:44:59 2024-04-26 am EDT			5-day change	1st Jan Change
18.1 ^EUR	-0.28%		-0.82%	-2.16%

Apr. 12	Indices up; Italy, industrial sales down	AN
Apr. 03	Transcript : Philogen S.p.A., 2023 Earnings Call, Apr 03, 2024

Philogen S p A : to attend the Italian Mid Cap Conference organised by Mediobanca on January 23-24, 2024

December 20, 2023 at 02:55 pm EST

2024, Events

Philogen to attend the Italian Mid Cap Conference organised by Mediobanca on January 23-24, 2024

Dec 18, 2023

The Italian Midcap Conference provides an opportunity for investors to get a perspective of Philogen progresses and to meet CEO Dario Neri and CFO Laura Baldi through a series of one-on-one meetings.

Attachments

Original Link
Original Document
Permalink

Disclaimer

Philogen S.p.A. published this content on 18 December 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 December 2023 19:54:31 UTC.

Latest news about Philogen S.p.A.

Indices up; Italy, industrial sales down	Apr. 12	AN
Transcript : Philogen S.p.A., 2023 Earnings Call, Apr 03, 2024	Apr. 03
Philogen reduces loss in 2023; NFP remains positive	Mar. 27	AN
Philogen S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Mib re-emerges in green; Saipem resumes rally	Mar. 07	AN
Futures await lists in red	Feb. 27	AN
Europeans down; Sogefi flies in Piazza Affari.	Feb. 26	AN
Philogen S.p.A. Provides Update on Pre-Planned Interim Analysis of the Phase III FIBROSARC Trial Investigating Onfekafusp Alfa in Patients with First-Line Advanced or Metastatic Soft Tissue Sarcoma	Feb. 20	CI
Mib in the red at 31,600; TIM still on top	Feb. 19	AN
European indexes down; TIM tops Mib	Feb. 19	AN
Futures bullish; PMI data coming in.	Jan. 24	AN
Mib gives ground; Saipem resists declines	Jan. 23	AN
Mib loses 30,000 points; MPS shines	Jan. 17	AN
Mib falls below 30,400; Amplifon tops	Jan. 08	AN
Piazza Affari down slightly; banks on the Mib do well	Jan. 08	AN
Philogen S.P.A. Announces Receipt of the Good Manufacturing Practice Certificate for Its New Production Facility in Rosia (Siena, Italy) by Competent Authorities	Dec. 05	CI
Cucinelli on Mib in December; Philogen, d'Amico and SAES on Mid	Nov. 23	AN
Philogen, net financial position falls in third quarter	Nov. 08	AN
Philogen has purchased 3,300 shares of its own common stock	23-10-23	AN
Transcript : Philogen S.p.A. - Special Call	23-10-18
Philogen purchased 10,400 shares of its own common stock	23-10-17	AN
Philogen S.P.A. and Sun Pharmaceutical Industries Limited Announces Positive Results from the Phase III Pivotal Trial in Patients with Locally Advanced Fully Ressectable Melanoma	23-10-16	CI
Philogen announces positive Phase III results for Nidlegy	23-10-16	AN
Philogen purchased approximately 8,000 shares of its own common stock	23-10-09	AN
Philogen purchased more than 5,400 shares of its own common stock	23-10-02	AN

Chart Philogen S.p.A.

Duration

Period

More charts

Company Profile

Philogen SpA is an Italy-based company, operating in the biotechnology sector. The Company develops products and technologies for the diagnosis and therapy of serious human diseases. It has three anti-cancer antibody derivatives, produced with an in-house industrial process, into Phase I/II clinical studies. The majority of its technologies and products are based on high-affinity human monoclonal antibody fragments. Philogen SpA developed a patented technology, Iterative Colony Filter Screening, for the isolation of monoclonal antibodies, which requires neither immunization nor phage display. The Company's subsidiaries are Philotec, Philomed and Philochem. Philogen SpA is headquartered in Siena, Italy.

Sector

Biotechnology & Medical Research

Calendar

2024-04-28 - Shareholder Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Philogen S.p.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

18.1 EUR

Average target price

23.5 EUR

Spread / Average Target

+29.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PHILOGEN S.P.A.	-2.16%	779M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs